Empagliflozin : a new treatment option for patients with type 2 diabetes mellitus
Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved..
Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. In clinical trials, empagliflozin demonstrated significant improvements in glycemic control, as monotherapy and in combination regimens. In addition, empagliflozin was associated with weight loss and moderate reductions in blood pressure. In the EMPA-REG OUTCOME study, empagliflozin significantly reduced the risk of the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Across the trials in general, empagliflozin was well tolerated, with no increased risk of hypoglycemia except when used with an insulin secretagogue or insulin. An increased risk of genital infections and urinary tract infections has been reported, although the association is less clear for urinary tract infections. Overall, empagliflozin appears to be a promising treatment for T2DM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 51(2015), 9 vom: 16. Sept., Seite 519-35 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dailey, G E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2015 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2015.51.9.2368554 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM253886872 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM253886872 | ||
| 003 | DE-627 | ||
| 005 | 20231224171203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2015.51.9.2368554 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0846.xml |
| 035 | |a (DE-627)NLM253886872 | ||
| 035 | |a (NLM)26488032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dailey, G E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Empagliflozin |b a new treatment option for patients with type 2 diabetes mellitus |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2015 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved. | ||
| 520 | |a Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. In clinical trials, empagliflozin demonstrated significant improvements in glycemic control, as monotherapy and in combination regimens. In addition, empagliflozin was associated with weight loss and moderate reductions in blood pressure. In the EMPA-REG OUTCOME study, empagliflozin significantly reduced the risk of the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Across the trials in general, empagliflozin was well tolerated, with no increased risk of hypoglycemia except when used with an insulin secretagogue or insulin. An increased risk of genital infections and urinary tract infections has been reported, although the association is less clear for urinary tract infections. Overall, empagliflozin appears to be a promising treatment for T2DM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 7 | |a Benzhydryl Compounds |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glucosides |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a SLC5A2 protein, human |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a empagliflozin |2 NLM | |
| 650 | 7 | |a HDC1R2M35U |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 51(2015), 9 vom: 16. Sept., Seite 519-35 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2015 |g number:9 |g day:16 |g month:09 |g pages:519-35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2015.51.9.2368554 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2015 |e 9 |b 16 |c 09 |h 519-35 | ||